MR辅助局灶挽救性HDR前列腺近距离放疗的更新结果:一项前瞻性研究
这项前瞻性研究纳入59例既往放疗后活检证实、MR可见局部复发前列腺癌患者,接受MR辅助超声引导局灶挽救性HDR近距离放疗(27 Gy/2次)。中位随访54个月,3年生化无失败生存率54%,免于ADT或再次挽救治疗率82%,迟发3级泌尿毒性仅1例,提示该方案耐受性好且有效。
要点
- 局灶挽救性HDR近距离放疗27 Gy/2次,3年生化无失败生存率54%。
- 3年免于ADT或再次挽救治疗率为82%,迟发3级泌尿毒性仅1例。
- 55例复查MRI中46例(84%)完全缓解,8例(15%)前列腺内其他部位复发。
核心结论
- 局灶腺体挽救性HDR近距离放疗耐受性好且有效。
研究设计与样本
- 前瞻性研究,纳入59例既往外照射和/或近距离放疗后活检证实、MR可见局部复发的前列腺癌患者。
主要发现
- 中位随访54个月(范围11–132个月),1例(1.7%)需临时导尿,仅1例迟发3级泌尿毒性。
- 3年生化无失败生存率为54%,3年免于ADT或再次挽救治疗率为82%。
- 55例HDR后中位464天复查MRI,46例(84%)完全缓解,9例持续存在病灶。
- 8例(15%)在前列腺其他部位复发。
关键数值与推荐
- 处方剂量为27 Gy分2次,间隔1–2周。
- 未使用辅助雄激素剥夺治疗(ADT)。
- HDR前中位PSA为4.13 ng/mL(范围1.30–11.63)。
临床怎么用
- 对于既往放疗后MR可见局部复发的前列腺癌患者,可考虑MR辅助超声引导局灶挽救性HDR近距离放疗。
局限性
- 样本量59例,单臂前瞻性设计,长期随访数据仍有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Focal salvage high dose-rate (HDR) prostate brachytherapy has emerged as a standard option for radiorecurrent prostate cancer. However, long-term prospective data remains limited. Our prospective study aimed to explore the toxicities, health-related quality of life (HRQOL) and efficacy of focal salvage HDR prostate brachytherapy. This report represents the updated results of the final cohort of patients. MATERIAL AND METHODS: Patients with biopsy-confirmed, MR-visible local recurrent prostate cancer after previous external-beam radiotherapy (XRT) and/or brachytherapy were eligible. MR-assisted, ultrasound-based focal HDR prostate brachytherapy with a prescription dose of 27 Gy in 2 fractions separated by 1-2 weeks apart was delivered. Adjuvant androgen deprivation therapy (ADT) was not used. RESULTS: 59 patients were enrolled in the study. Median follow up from salvage HDR was 54 months (11-132). The initial treatment was XRT only in 20 (34 %) and brachytherapy +/- XRT in 39 (66 %). The pre-HDR median PSA was 4.13 ng/mL (1.30-11.63). Twenty-five (42 %) were staged with a PSMA PET scan. One patient (1.7 %) required temporary urinary catheterization. There was only 1 grade 3-5 toxicity, a late grade 3 GU toxicity. Three-year biochemical failure-free survival and freedom from ADT or repeat salvage therapy rate was 54 % and 82 %, respectively. Of the 55 patients who had a post-HDR MRI (median 464 days), 46 (84 %) patients had a complete response and 9 had persistent disease. 8 (15 %) patients recurred elsewhere in the prostate. CONCLUSION: Our toxicity and PSA failure-free results suggest that focal gland salvage HDR brachytherapy is well tolerated and effective. CLINICALTRIALS: gov identifier NCT01583920.
引用
- Paulin G, Morton G, Loblaw A, et al. Updated results of MR-assisted focal salvage HDR prostate brachytherapy: a prospective study. Radiother Oncol. 2025. PMID: 40789422. doi:10.1016/j.radonc.2025.111091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。